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The steroidogenic acute regulatory (StAR) protein, a novel mitochondrial protein, is involved in the regulation of steroid hormone 
biosynthesis through its mediation of the intramitochondrial transport of the steroid substrate, cholesterol, to the cytochrome P450 
cholesterol side chain cleavage (P450scc) enzyme. The expression of StAR protein is regulated by cAMP-dependent signaling in 
steroidogenic cells. During the course of our studies in mouse Leydig cells, we employ several methods for studying the regulation of 
StAR protein expression by human chorionic gonadotropin (hCG). A sensitive quantitative reverse transcription and polymerase chain 
reaction (RT-PCR) was utilized for determining StAR mRNA expression. Stimulation of mLTC-1 mouse Leydig tumor cells with hCG 
resulted in the coordinate regulation of StAR mRNA expression and progesterone accumulation in a time-response manner. The 
validity and accuracy of quantitative RT-PCR results in mLTC-1 cells were verified by a competitive PCR approach and were further 
confirmed in primary cultures of isolated mouse Leydig cells. Immunoblotting studies demonstrated an increase in the levels of the 
StAR protein in a concentration dependent manner following hCG stimulation in mLTC-1 cells. Northern hybridization analysis 
revealed three StAR transcripts, all of which were of sufficient size to encode functional StAR protein, and which were coordinately 
expressed in response to hCG. Collectively, the experimental approaches utilized in the present investigation allow for the 





The classical mechanism utilized in tropic hormone-responsive 
steroid synthesis occurs through an increase in intracellular 
cAMP, which, in turn, triggers a regulatory cascade resulting in 
the mobilization and delivery of cholesterol from the outer to the 
inner mitochondrial membrane (1-3). Indeed, the 
intramitochondrial transport of cholesterol is the rate-limiting 
and regulated step in steroidogenesis and is dependent on de novo 
protein synthesis, as inhibitors of protein synthesis have been 
shown to decrease the steroidogenic response (4-6). It has been 
found that the inhibitor-sensitive step is present in the 
mitochondria and that protein synthesis inhibitors have no effect 
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on the activity of cytochrome P450 cholesterol side chain 
cleavage (P450scc) complexes or on cholesterol accumulation in 
the outer mitochondrial membranes (2, 7). Therefore, the acute 
production of steroids requires a trophic hormone induced, 
rapidly synthesized, and cycloheximide sensitive regulatory 
protein that is involved in the transfer of cholesterol from the 
outer to the inner mitochondrial membrane (2-3, 7-8). Among 
the candidate regulatory proteins proposed in this transfer, the 
steroidogenic acute regulatory (StAR) protein has essentially all 
the necessary characteristics for cholesterol delivery and the 
initiation of steroidogenesis (9-10). The purification, cloning, and 
expression of the novel mitochondrial protein, StAR, was carried 
out for the first time in MA-10 mouse Leydig tumor cells (11). 
Since then cDNA clones for StAR have been isolated from rat 
(12), human (13), ovine (14), bovine (15), porcine (16), equine 
(17), monkey (GenBank accession no. AY007224) and hamster 
(18), and a high degree of homology has been demonstrated 
among these species.  
 
The endocrine regulation of Leydig cell function occurs 
predominantly through the action of luteinizing hormone 
(LH)/hCG, interacting with its cognate receptor and coupling to 
the adenylate cyclase signal transduction system. It has been 
demonstrated that LH, its “superagonist” hCG, and analogs of 
their second messenger, cAMP, (dibutyryl cAMP, 8-bromo-
cAMP), coordinately increase StAR protein and StAR mRNA 
levels in a time frame that is consistent with increased steroid 
production in mouse Leydig cells (10, 19-21). Also, StAR 
expression has been predominantly associated with the steroid 
producing cells of the testis, adrenal, and ovary in the adult (20, 
22-23). While cAMP mediated signaling is the principle 
mechanism regulating StAR expression, several other agents 
and/or signals appear to play critical roles in this regulatory 
process (24-25). It is noteworthy, however, that the inhibition of 
StAR protein expression at the transcriptional or translational 
level results in a dramatic inhibition of steroid biosynthesis (26-
28). Furthermore, compelling evidence regarding the role of the 
StAR protein in the regulation of steroidogenesis has been 
further implicated by targeted disruption of the StAR gene and 
by the study of patients suffering from lipoid congenital adrenal 
hyperplasia, both of which result in severe impairment of adrenal 
and gonadal steroid synthesis due to mutations in the StAR gene 
(22-23, 29-30). Thus, StAR protein plays an indispensable role in 
steroid biosynthesis by controlling the rate-limiting step i.e. the 
delivery of cholesterol from the outer to the inner mitochondrial 
membrane in steroidogenic cells. The present studies utilized 
several methods in demonstrating the regulation of StAR protein 
expression by hCG, using the murine Leydig tumor cell line 
(mLTC-1) as an experimental model (31). 
 
MATERIALS AND METHODS 
 
Cell culture and stimulation experiments  
 
Mouse Leydig tumor cells (mLTC-1) were obtained from 
American Type Culture Collection (ATCC, Manassas, VA) and 
maintained in RPMI 1640 medium as described previously (31-
32). Cells were cultured in growth medium at 37°C under a 
humidified atmosphere of 95% air and 5% CO2. During splitting, 
the viability of the cells was determined with 0.4% trypan blue 
(w/v) exclusion. Cells were sub-cultured at a density of 5 x 104 
cells/well in 24-well plates or 1.5 x 105 cells/well in 6-well plates 
for different experiments and grown for 24 h prior to their use in 
experiments.  
 
On the day preceding an experiment, cells were washed two 
times with 0.01 M phosphate-buffered saline (PBS) and replaced 
with serum-free RPMI medium. The additives, stimulators 
and/or inhibitors [hCG (CR-127, 14,900 IU/mg, NHPP, 
Bethesda, MD) at 0-500 ng/ml as indicated in specific 
experiments; actinomycin D and cycloheximide (Sigma-Aldrich, 
St. Louis, MO) at 10 µg/ml], were constituted fresh, diluted, and 
applied to cells in serum-free medium. Cells were processed for 
total RNA or mitochondrial protein isolation, and the 
accumulation of progesterone in the medium (in specific 
experiments) was determined by specific radioimmunoassay.  
 
Isolation, preparation, and incubation of mouse 
Leydig cells  
 
Testicular Leydig cells from adult mouse (C57BL/6 strain, 2-3 
months of age) were isolated and cultured utilizing procedures 
described previously (33-36). Testes were de-capsulated, 
interstitial cells were isolated in Dulbecco’s Modified Eagle’s 
Medium (DMEM)/F12 (Gibco-BRL, Life Technologies, 
Grand Island, NY) containing 25 mM Hepes, pH 7.4, 18 mM 
NaHCO3 and 0.2% BSA (w/v), and dispersed by collagenase 
[0.2% (w/v), 22 min, 34°C, 95% O2/5% CO2]. Cells were filtered 
through sterile nylon gauze (mesh 0.5-0.8 mm) and washed with 
DMEM/F12 medium to remove the collagenase. Following 
washing, cells were purified using continuous Percoll (Amersham 
Biosciences AB, Uppsala, Sweden) density gradient (range 1.01-
1.126 kg/L) centrifugation. During centrifugation, cell types 
partitioned as a result of their individual buoyant densities, and 
the Leydig cells, which gathered at approximately 1.07 kg/L of 
Percoll, were collected, washed, and plated for further 
experiments (34-35). The purity of the Leydig cells was assessed 
histochemically by 3β-hydroxysteroid dehydrogenase staining and 
approximately 70-80% of the cells were found to be positive (33). 
These cells were sub-cultured in DMEM/F12 growth medium 
supplemented with 10000 U/L penicillin and 50 mg/L 
streptomycin, at a density of 5 x 105 cells/well in 6-well plates. 
Following 48 h of plating, these cells were used for experiments. 
 
Extraction of RNA, and quantitative reverse 
transcription and polymerase chain reaction (RT-
PCR) (Protocol I)  
 
Total RNA was extracted from control and hCG stimulated cells 
using Trizol reagent (Invitrogen life technologies, Carlsbad, 
CA), as described previously (32, 37). The isolation and 
amplification of mLTC-1 cell StAR cDNA were carried out 
utilizing primers designed from the mouse StAR cDNA sequence 
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(11). The sense primer, 5’-
GACCTTGAAAGGCTCAGGAAGAAC-3’, and the antisense 
primer, 5’-TAGCTGAAGATGGACAGACTTGC-3’, spanned 
bases -51 to -27 and 931 to 908 respectively, relative to the first 
base of the translation initiation codon. The variation in RT-PCR 
efficiency was evaluated with the L19 ribosomal protein gene as 
an internal control, using the sense primer 5’-
GAAATCGCCAATGCCAACTC-3’ (bases 154 to 173) and the 
antisense primer 5’-TCTTAGACCTGCGAGCCTCA-3’ (bases 
559 to 540) (38). 
 
RT and PCR of the target genes were run sequentially in the 
same assay tube as described previously (32, 35, 39). Briefly, total 
RNA (1-2 µg) from different experimental groups was reverse 
transcribed using avian myeloblastosis virus reverse transcriptase 
(AMV-RT; Promega Corporation, Madison, WI) and the 
antisense primers. StAR and L19 cDNAs generated were further 
amplified by PCR using the primer pairs listed above. The total 
reaction volume was 50 µl and contained 1 nM of each oligo 
primer, 200 µM of a deoxy-NTP mixture including [α32P]-CTP, 
20 U RNasin, 5 U AMV-RT and 2.5-5 U Taq DNA polymerase 
in 1 x PCR buffer [20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.1 
mM EDTA, 1 mM DTT, 50% glycerol (v/v), 0.5% Nonidet-P40 
(v/v) and 0.5% Tween-20 (v/v)]. The reaction was initiated at 
50°C for 15 min (RT) followed by denaturation at 97°C for 5 
min. Then PCR was performed using a variable number of cycles 
of amplification that were defined by denaturation at 96°C for 
1.5 min, annealing at 55°C for 1.5 min and extension at 72°C for 
3 min (PTC-100, Programmable Thermal Controller, MJ 
Research, Inc., Waltham, MA). The number of PCR cycles 
utilized was 19, which were optimized to be in the exponential 
phase of the PCR (21, 35). A final cycle of extension at 72°C for 
16 min was also included. A 20-µl aliquot of each PCR product 
was analyzed by gel electrophoresis on a 1.2% agarose (w/v) gel. 
The molecular sizes of the amplified products (StAR and L19) 
were determined by comparison with the molecular weight 
markers (100 bp DNA ladder, Promega) run in parallel with RT-
PCR products. The gels were then vacuum dried, exposed to X-
ray films (Marsh Bio Products, Inc., Rochester, NY) at room 
temperature for 1 to 3 h, and the relative levels of the different 
signals were quantified using a computer-assisted image analysis 
system (Visage 2000, BioImage, Ann Arbor, MI). The integrated 
optical density (IOD) values for StAR in each band were 
normalized with the corresponding L19 expression, and the level 
of StAR mRNA in response to hCG was determined. 
 
Quantitative competitive RT-PCR  
 
This procedure was employed by generating a competitor of 
StAR from the mouse StAR cDNA (35). Briefly, full length StAR 
cDNA produced by RT-PCR was sub-cloned into the pGEM T-
vector following the instructions of the manufacturer (Promega).  
 
Analysis of restriction sites in the mouse StAR cDNA 
demonstrated the presence of two AvaI sites. Taking advantage 
of the two AvaI sites, the sub-cloned product was digested and 
separated in a 1.2% agarose (w/v) gel. Following electrophoresis, 
a 407-bp band consisting of the AvaI fragment from the full 
length StAR cDNA was excised from the gel. The remaining 
fragments (StAR cDNA sub-cloned into pGEM T-vector) were 
subjected to blunt-end ligation by the Klenow fragment of DNA 
polymerase I, and the strand was re-circularized by T4 DNA 
ligase (Promega). Thus, a StAR cDNA containing a 407-bp 
deletion was generated and inserted into the cloning site of the 
pGEM T-vector. The identity of all inserted fragments was tested 
by restriction endonuclease digestion and confirmed by 
sequencing. Transcription of the ApaI linearized template with 
the Sp6 RNA polymerase (Promega) generated a sense cRNA of 
approximately 570 bp in length, a fragment that was used as the 
StAR competitor. To perform competitive RT-PCR, decreasing 
concentrations of the StAR competitor (homologous cRNA, 
1000-9.3 ng) were amplified together with a fixed amount of total 
RNA (1 µg from control and treated groups), using the same 
primer pairs utilized above. The molecular sizes of the RT-PCR 
products (StAR, StAR competitor and L19) were determined in 
1.2% agarose (w/v) gels that were vacuum dried and following 
exposure to X-ray films, the bands were quantified as above 
(Visage 2000). The IOD values (StAR/StAR competitor) were 
normalized with the corresponding L19 expression, and the 
response of hCG on StAR mRNA expression was assessed. 
 
Isolation of mitochondria and immunoblotting 
(Protocol II)  
 
Isolation of mitochondria from mLTC-1 cells was performed by 
differential centrifugation (21, 37). Cells were washed with 0.01 
mM PBS, scraped, and collected into a Tris-sucrose-EDTA 
buffer (10 mM Tris-HCl, pH 7.2, 250 mM sucrose, 0.1 mM 
EDTA) containing 1.0 mM phenyl methyl sulfonyl fluoride as a 
protease inhibitor. Cells were homogenized at 4°C (1200 rpm, 30 
strokes) with a Potter-Elvehjem homogenizer. The homogenate 
was centrifuged at 600 x g for 25 min to remove broken cell 
debris and nuclei, and the resulting supernatant was further 
centrifuged at 9000 x g for 25 min. The pellet containing 
mitochondria was washed two times in the same buffer and 
recovered by centrifugation at 9000 x g for 10 min. 
 
Mitochondrial protein (20 µg) was solubilized in sample buffer 
[25 mM Tris-Cl, pH 6.8, 1% sodium dodecyl sulphate (SDS, 
w/v), 5% β-mercaptoethanol (v/v), 10% glycerol (v/v) and 
0.01% bromophenol blue (v/v)] and loaded onto a 12% SDS 
(w/v)-polyacrylamide gel electrophoresis (SDS-PAGE) (Mini 
Protean II System, Bio-Rad), as described by Laemmli (40), with 
minor modifications (21, 37). Electrophoresis was performed at 
200 V for 1 h and the proteins were electrophoretically 
transferred onto Immuno-Blot PVDF Membrane (Bio-Rad, 
Hercules, CA). The membranes were incubated in a blocking 
buffer [Tris-buffered saline, TBS containing 0.2% Tween-20 
(v/v) and 4% Carnation non-fat dry milk (w/v)] for 1 h at room 
temperature, and followed by incubation for an additional 1 h 
with anti-peptide antibodies (1:20000 dilution) generated in 
rabbits against an amino acid fragment (88-98) of the StAR 
protein (11). The membranes were washed three times (10 min 
each) in TBS buffer and incubated for 1 h at room temperature 
with horseradish peroxidase-labeled goat anti-rabbit IgG 
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(1:20000) (Biosource International, Camarillo, CA). The 
membranes were washed again as above, and immunodetection 
of the StAR protein was performed with a Chemiluminescence 
Imaging Western Lightning Kit (PerkinElmer, Boston, MA). The 
membranes were exposed to X-ray films for 1-3 min (Marsh Bio 
Products), and the immuno-specific StAR band was quantified as 
above (Visage 2000). 
 
Northern hybridization analysis (Protocol III)  
 
Total RNA was isolated from different treatment groups using 
Trizol reagent (Invitrogen). Total RNA (15-20 µg) was resolved 
on 1.2% denaturing formaldehyde agarose (w/v) gels and 
transferred onto Hybond-N+ nylon membranes (Amersham 
Pharmacia Biotech, Piscataway, NJ) by employing the capillary 
transfer method. An antisense cRNA probe corresponding to 
bases -27 to 931, a NotI fragment of the StAR cDNA, was 
utilized in Northern analysis for detection of the StAR mRNA 
expression. This fragment was produced by in vitro transcription 
(Promega) with T7 RNA polymerase, dNTPs and [α32P]-UTP 
(specific activity, ~30 TBq/mmol; Amersham Pharmacia 
Biotech). The 32P-labeled probes were purified using Sephadex 
G-50 nick columns (Amersham Pharmacia Biotech). Pre-
hybridization and hybridization were carried out under stringent 
conditions (21, 28). Pre-hybridization was carried out for 6 h at 
65°C in a solution containing 50% formamide (v/v), 3 x SSC 
(150 mM NaCl, 50 mM sodium citrate, pH 7.0), 5 x Denhardt’s 
solution, 1% SDS (w/v), 0.1 mg/ml heat-denatured calf thymus 
DNA and 100 µg/ml yeast tRNA. Hybridization was performed 
at 66°C for 16 h in the same solution after addition of the 32P-
labeled probe. In the case of the human glyceraldehyde-3-
phosphate dehydrogenese (GAPDH) cDNA probe, pre-
hybridization and hybridization were carried out at 42°C. The 
membranes were washed twice at room temperature for 20 min 
with 2 x SSC containing 0.1% SDS (w/v), followed by 2 h at 
66°C with 0.1 x SSC and 0.1% SDS (w/v) until removal of the 
background counts. The membranes were then exposed to X-ray 
films (Marsh Bio Products) for 36-48 h at -80°C. To examine the 
variation in StAR mRNA expression, the membranes were 




Statistical analysis was performed using one-way ANOVA 
followed by Fisher’s protected least significant differences test 
using the Statview Program (Abacus Concepts Inc., Berkeley, 
CA). Data represent the mean ± S.E., and P < 0.05 was 
considered to be statistically significant. 
 
RESULTS AND DISCUSSION 
 
Assessment of hCG function in mouse Leydig cells, 
and the regulation of StAR expression  
 
The steroidogenic acute regulatory (StAR) protein has been 
implicated in the regulation of steroid biosynthesis by virtue of its 
expression through cAMP dependent mechanisms in 
steroidogenic cells. Thus, StAR expression has been 
demonstrated to respond rapidly to various signals that regulate 
steroidogenesis in the adrenals and gonads (25, 41). LH/hCG 
plays a key role in regulating various Leydig cell functions 
including steroid biosynthesis through activation of multiple 
second messenger systems, as well as by intratesticular autocrine 
and paracrine impulses (42-44). In particular, the interaction of 
LH/hCG with its specific receptors on Leydig cell membranes is 
followed by a sequence of events that lead to intracellular 
modifications and the stimulation of steroidogenesis (45-46). 
Given the importance of the StAR protein in this process, the 
involvement of hCG in the regulation of StAR expression was 
investigated in mouse Leydig cells. 
 
Fig. 1: Temporal response pattern of hCG stimulated StAR mRNA 
expression and progesterone production in mLTC-1 cells. A representative 
autoradiogram illustrates StAR mRNA expression in response to hCG at different 
times (0-36 h), as determined by quantitative RT-PCR (panel A). Panel B 
illustrates the integrated optical density (IOD) of StAR mRNA expression at each 
time point after normalizing with the corresponding L19 bands (black bar). The 
production of progesterone in the media of the same samples was determined 
(white bar). Data represent the mean ± S.E. of three independent experiments. 
 
Treatment of mLTC-1 cells with hCG (50 ng/ml) resulted in a 
time dependent increase in the steady state levels of StAR mRNA 
and progesterone production (Fig. 1). hCG induced StAR mRNA 
expression was found to be significant (p < 0.05) at 1 h. The 
magnitude of the response reached a maximum of 6.8 ± 0.55 fold 
by 6 h, and thereafter StAR mRNA levels gradually declined. 
Although, the expression of StAR mRNA remained elevated over 
controls at all the time points studied. Progesterone accumulation 
in the media was measured at each time point, and was shown to 
parallel StAR mRNA levels (Fig. 1). The increase in progesterone 
in the media was significant within 1 h (p < 0.01), increased 
gradually to 37 ± 6.2 fold by 6 h, and then followed the pattern 
of StAR mRNA expression. In fact, following hCG stimulation, 
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the time course of StAR mRNA expression and progesterone 
production demonstrate an intimate relationship between the 
two, an observation that is in agreement with previous findings 
(20, 47).  
 
Fig. 2: Schematic representation of the competitive RT-PCR to verify the 
quantitative accuracy of hCG induced StAR mRNA expression in mLTC-1 
cells. Decreasing amounts of StAR competitor (1000-9.3 ng) were incubated with 
a fixed amount of total RNA from control and hCG-treated samples, as described 
in Materials and Methods. The IOD ratio of StAR/StAR competitor from both 
control and hCG-stimulated groups was corrected for using the corresponding 
intensity of the L19 bands. The situation where the amplicon ratio is 1 (horizontal 
line) indicates hCG induced StAR mRNA expression when compared with two 
experimental groups. Data represent the mean ± S.E. of two independent 
experiments. StAR comp, StAR competitor. 
 
In additional experiments, the accuracy and efficacy of the 
quantitative RT-PCR assay were verified by employing 
competitive PCR. To perform this, fixed amounts of total RNA 
(1 µg) obtained from control and hCG treated samples were 
allowed to compete with varying amounts of a StAR competitor 
(1000-9.3 ng). The results shown in Fig. 2 demonstrate that 
amplification of decreasing amounts of the competitor with fixed 
amounts of total RNA resulted in signals of decreasing intensity. 
In contrast, StAR mRNA expression decreased gradually as the 
concentrations of competitor increased, reflecting the specific 
nature of competitive PCR. The ratios of the intensities of StAR 
and StAR competitor in both cases were normalized with the 
corresponding L19 signals. The results of the competitive PCR 
clearly demonstrate that hCG induced a 6.7 fold increase in StAR 
mRNA expression when compared to control (horizontal line) 
(Fig. 2), an observation agreeing with and confirming the 
quantitative RT-PCR results (35).  
 
Several lines of evidence demonstrate that StAR expression is 
regulated by cAMP-dependent mechanisms and that its 
expression is fundamentally associated with steroid producing 
cells (10, 20, 22, 48). The present data are also consistent with 
previous studies that demonstrated stimulation of MA-10 cells 
with a cAMP analog coordinately increased StAR mRNA, StAR 
protein and steroid production (10, 20, 37). Also, in mouse 
Leydig cells, thyroid hormone has been reported to increase the 
levels of StAR protein and StAR mRNA, and their increased 
expression occurs in a time frame that parallels the acute 
production of steroids (28, 35, 49). It was also demonstrated that 
hCG and thyroid hormone (which mediate their actions through 
plasma membrane and nuclear receptor systems, respectively) 
have additive effects on StAR expression and steroidogenesis 
(35). Notably, a temporal relationship between the expression of 
the StAR gene and the capacity to produce steroid hormones has 
been demonstrated during development (20, 22-23). Never-
theless, the mechanism of hormone action on StAR expression, 
in most cases, is due to a cAMP-mediated change in StAR 
transcription and/or StAR mRNA stability. 
 
The functional relevance of hCG induced StAR mRNA 
expression in mLTC-1 cells was confirmed in primary cultures of 
isolated mouse Leydig cells. As determined by RT-PCR analysis 
(Fig. 3), stimulation of Leydig cells with hCG (50 ng/ml, 6 h) 
resulted in an approximate 2 fold increase in StAR mRNA 
expression when compared to controls. The accumulation of 
testosterone in the media was increased by 175% in response to 
hCG under a similar experimental paradigm (not illustrated), 
indicating the direct link between StAR expression and 
steroidogenesis. Taken together, these findings further strengthen 
the role of LH as a physiological regulator of various Leydig cell 
functions including steroidogenesis. 
 
 
Fig. 3: StAR mRNA expression in response to hCG in isolated adult mouse 
Leydig cells. A representative autoradiogram shows RT-PCR analysis of StAR 
mRNA expression using 2 µg of total RNA from control and hCG (50 ng/ml, 6 h) 
treated groups (upper panel). IOD values (lower panel), *, p < 0.05, control vs. hCG. 
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Given the temporal pattern of hCG mediated StAR mRNA 
expression and steroid production, the pattern of the 30-kDa 
form of the StAR protein in response to hCG was investigated in 
mLTC-1 cells. Cells stimulated for 6 h with varying 
concentrations of hCG (0-500 ng/ml) demonstrated a dose-
dependent increase in StAR protein levels (Fig. 4). The 
expression of StAR protein in response to hCG was detected (p 
< 0.05) at concentrations ≥ 5 ng/ml. The half-maximal 
stimulation occurred at 19 ng/ml, and the maximal increase at 
doses of ≥ 50 ng/ml (39). The involvement of hCG in StAR 
expression and steroidogenesis in Leydig cells has been 
demonstrated to be up-regulated by insulin-like growth factor–1 
and also by prolactin (36, 50). In addition, extracellular Ca2+ has 
been shown to increase the stimulatory action of hCG on StAR 
expression and steroid production in mouse Leydig cells (21). 
Consistent with the current data, several studies have shown a 
striking correlation between the synthesis of steroids and the 
expression of StAR protein (10, 35, 51-52). 
 
Fig. 4: Dose response pattern of hCG mediated StAR protein expression by 
immunoblotting. mLTC-1 cells were treated with varying doses of hCG (0-500 
ng/ml) for 6 h, and a representative autoradiogram (and corresponding IOD 
values) illustrates the expression of the 30-kDa StAR protein. Data are 
representative of two independent experiments. 
 
The roles of transcription and ongoing protein synthesis in hCG 
stimulated StAR expression were then evaluated. As illustrated in 
Fig. 5, mLTC-1 cells stimulated with hCG (50 ng/ml) for 6 h, or 
in the presence of actinomycin D (Act. D., inhibits RNA 
synthesis) and cycloheximide (Chx., inhibits protein synthesis), 
demonstrated an attenuation of StAR mRNA expression in 
response to hCG. A full length mouse StAR probe hybridized 
with three transcripts at 3.4, 2.7 and 1.6 kb, and all of them 
showed coordinated up-regulation by hCG. This observation is 
in agreement with previous findings that demonstrated the 
presence of three or four StAR transcripts of 3.4, 2.7, 1.6, and 1.4 
kb in the mouse (20-21, 35, 53), and three of 7.4, 4.4, and 1.6 kb 
in the human (13). Act. D. and Chx. have been demonstrated to 
inhibit hCG and/or cAMP stimulated StAR expression and 
steroid production in MA-10 Leydig and human granulosa-lutein 
and thecal cells (26, 47-48). The present data also conform to the 
observation that inhibition of StAR expression at the level of 
transcription or translation results in a marked decrease in steroid 
synthesis (26-28, 48), and further demonstrates that StAR plays a 
crucial role in regulating steroid biosynthesis.  
 
Fig. 5: StAR mRNA expression in mLTC-1 cells in response to hCG 
stimulation requires transcription and ongoing protein synthesis. A 
representative autoradiogram of a Northern blot (upper panel) illustrates the 
apparent molecular sizes of the different StAR transcripts. The GAPDH mRNA 
expression demonstrates equal RNA loading (lower panel). Similar results were 
obtained from three independent experiments. 
 
Trophic hormone or cAMP analog stimulation increases PKA 
activity, which then results in the induction of StAR protein 
expression. In mouse Leydig cells it was presently demonstrated 
that hCG was able to increase the expression of StAR mRNA, 
StAR protein and steroidogenesis in a time- and dose-responsive 
manner and did so utilizing a mechanism that required ongoing 
protein synthesis. While cAMP-mediated signaling regulates 
expression of the StAR gene, its promoter lacks a consensus 
cAMP response-element (CRE). The mechanism regulating StAR 
transcription in the absence of a canonical CRE has been 
demonstrated to be mediated by multiple DNA elements that are 
found to be located in a transcription factor-binding site-rich 
region in the StAR promoter (reviewed in Ref. 24). StAR 
expression has also been influenced by various compounds, 
including peptide and non-peptide hormones, growth factors, 
gonadotropin-releasing hormone, prostaglandins and steroids, 
acting through endocrine, autocrine and paracrine mechanisms 
(36, 43, 50, 54-56). It has also been demonstrated that 
phosphorylation of the StAR protein is critical in producing full 
cholesterol transferring activity (57-58). Moreover, several 
additional intracellular factors involved in various signaling 
pathways have also been demonstrated to be instrumental in 
regulating StAR expression, including calcium messenger systems, 
arachidonic acid metabolites, chloride ion channels, and mitogen 
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activated protein kinase/extracellular signal-related kinases (21, 
25, 59-64). Based on these many observations, it is highly likely 
that the combined action of multiple factors and signaling 
pathways are involved in controlling hCG mediated StAR 
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Protocol I: Quantitative RT-PCR 
 
1. Isolate total RNA from mLTC-1 cells of different treatment groups with Trizol reagent (Invitrogen) or any commercially available 
product according to the manufacturer’s instructions.  
2. At the end of extraction, resuspend total RNA in diethyl pyrocarbonate (DEPC)-treated water, and determine the purity of the 
RNA by scanning with a spectrophotometer at a wavelength of 220-320 nm. Dilute the total RNA in DEPC water (1-2 µg/5 µl) on 
ice and use it directly in the RT-PCR assay.  
3. Resuspend the specific primer pairs (see Materials and Methods) in nuclease-free water for the isolation and amplification of StAR 
cDNA from mLTC-1 cells. Similarly, dilute the 2nd primer pairs (L19, as an internal control) to verify RT-PCR efficiency.  
4. The total reaction volume should be 50 µl. Perform RT and PCR of the target genes sequentially in the same assay tube.  
5. Prepare an incubation mixture which includes all the oligo primers (1 nM of each, 5 µl), 200 µM of a deoxy-NTP mixtures (GTP, 
TTP, ATP, and CTP) containing [α32P]-CTP (2 µl), 20 U RNasin (RNAse inhibitor. 0.5 µl), 5 U AMV-RT (0.5 µl) and 2.5-5 U Taq 
DNA polymerase (0.5-1.0 µl) in 1 x PCR buffer (see Materials and Methods). Adjust the total volume with nuclease-free water. 
6. Add total RNA to the incubation mixture. Mix gently and add a drop or 25 µl of mineral oil (Sigma-Aldrich) to prevent evaporation 
during the RT-PCR. Mix again, centrifuge (800 rpm for 1 min at 4°C) and place the reaction tubes (0.5 ml thin-walled) in the 
thermal controller (MJ Research Inc.). 
7. Run a program for RT and PCR at the same time using a programmable thermal controller (MJ Research Inc.). Start the reaction at 
50°C for 15 min (RT) followed by denaturation at 97°C for 5 min. Following RT, run the PCR with a variable number of cycles 
that are defined by denaturation at 96°C for 1.5 min, annealing at 55°C for 1.5 min and extension at 72°C for 3 min.  
8. Evaluate the varying numbers of PCR cycles (exponential, linear and plateau phases) for StAR expression and choose one that is in 
the exponential phase of the PCR. Under the present incubation conditions, 19 cycles were chosen for further analysis (31, 35). 
Utilize a final cycle of extension at 72°C for 16 min. Prepare an 1.2% agarose (w/v) gel following standard procedures to examine 
the PCR products by gel electrophoresis. Use 0.5 x TBE (0.05 M Tris-borate and 1.0 mM EDTA) as the running electrophoresis 
buffer. 
9. Electrophorese an aliquot (20 µl) of each PCR product in the gel. The molecular sizes of the amplified products (approximately 980 
bp for StAR and 405 bp for L19) were determined by comparison with the molecular weight markers (100 bp DNA ladder, 
Promega) run in parallel with the RT-PCR products. 
10. Vacuum dry the gels and expose them to X-ray films (Marsh Bio Products) at room temperature for 1-3 h. 
11. Quantify the relative levels of the different signals using an image analysis instrument (such as the Visage 2000), and normalize the 
expression of StAR mRNA in each band to the corresponding L19 expression. 
 
Protocol II: Mitochondrial isolation, SDS-PAGE, and immunoblotting 
 
1. Following treatment, wash mLTC-1 cells with 0.01 mM PBS. Collect cells for isolation of mitochondria by differential 
centrifugation in Tris-sucrose-EDTA buffer containing protease inhibitor (see Material and Methods). 
2. Homogenize cells at 4°C (1200 rpm, 30 strokes) with a motor driven, glass-teflon homogenizer. Centrifuge the homogenate at 500 
x g for 25 min to remove broken cell debris and nuclei. Centrifuge the resulting supernatant at 9000 x g for 25 min to pellet the 
mitochondria. 
3. Wash the pellet two times by resuspension and centrifugation at 9000 x g for 10 min in Tris-sucrose-EDTA buffer. Resuspend the 
pellet, measure the protein content (65), and store at -80°C until use. 
4. Cast a 12% SDS (w/v)-PAGE gel following a standard protocol according to the procedure of Laemmli (40). 
5. Solubilize 20 µg of mitochondrial protein in sample buffer (see Materials and Methods) and load onto the 12% SDS (w/v)-PAGE 
(Mini Protean II System, Bio-Rad). 
6. Perform electrophoresis at 200 V for 1 h.  
7. Transfer the proteins electrophoretically onto Immuno-Blot PVDF Membrane (Bio-Rad) at 100 V for 1 h.  
8. Incubate the membranes in a blocking buffer [TBS with 0.2% Tween-20 (v/v) and 4% non-fat dry milk (w/v)] with slow shaking 
for about 1 h at room temperature or overnight at 4°C. 
9. Incubate with anti-StAR peptide antibodies (1:20000) with slow shaking for 1 h. 
10. Wash the membranes three times (10 min each) in TBS buffer and incubate for 1 h at room temperature with horseradish 
peroxidase-labeled goat anti-rabbit IgG (1:20000). 
11. Wash the membranes again as described above. Detect the StAR protein using the Chemiluminescence Imaging Western Lightning 
Kit (PerkinElmer).  
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12. Expose the membranes for 1-3 min to X-ray films (Marsh Bio Products) and quantify the immuno-specific StAR band as described 
above. 
 
Protocol III: Northern blotting 
 
1. Isolate total RNA from mLTC-1 cells with Trizol reagent (Invitrogen) or any commercially available product according to the 
manufacturer’s instructions.  
2. Prepare and cast a 1.2% denaturing formaldehyde agarose gel [agarose (1.2 gm, w/v), 10 x Mops (Sigma-Aldrich) buffer (10 ml), 
DEPC water (73 ml), formaldehyde (37%, v/v; 17 ml)] following standard protocol. 
3. Incubate total RNA (15-20 µg) at 65°C for 5-8 min in a mixture containing de-ionized formamide (12.5 µl), 10 x Mops buffer (2.5 
µl), formaldehyde (4 µl), ethidium-bromide (0.1 µl) and then chill on ice. Add 2.5 µl of 6 x loading dye (Promega). 
4. Electrophorese the samples for 14-16 h in 1 x Mops buffer at 25 V.  
5. Transfer the RNA onto a Hybond-N+ nylon membrane (Amersham Pharmacia Biotech) using the capillary transfer method. Fix 
the RNA under UV light, dry the membranes and store at 4°C until use. 
6. Prepare a cRNA probe, a NotI fragment of the mouse StAR cDNA, by in vitro transcription (see Materials and Methods). The 
reaction mixture should include 5 x labeling buffer (5 µl), DNA template (~100 ng), dNTPs (1 µl), nuclease-free BSA (1 µl), T7 
RNA polymerase (1 µl), and [α32P]-UTP (2.5 µl). Adjust the total volume to 25 µl with nuclease-free water. 
7. Incubate the mixture at 37°C for 1 h, add RQ1 RNAse-free DNAse (5 µl, Promega) and incubate again for 15 min. Purify the 32P-
labeled probes using a Sephadex G-50 nick column by eluting with 0.5 M Tris-EDTA (pH 8.0) containing 20% SDS (w/v).  
8. Pre-hybridize the membranes for 6 h at 65°C in a solution containing 50% formamide (v/v), 3 x SSC, 5 x Denhardt’s solution (see 
Molecular Cloning, Cold Spring Harbor Laboratory, 1989, Volume 2, pp 9.47-9.49) 1% SDS (w/v), 0.1 mg/ml heat-denatured calf 
thymus DNA and 100 µg/ml yeast tRNA, under stringent conditions. 
9. Add 32P-labeled probe to the same solution and hybridize the membranes at 66°C for 16 h. Wash the membranes at room 
temperature for 20 min with 2 x SSC containing 0.1% SDS (w/v), followed by 2 h at 66°C with 0.1 x SSC and 0.1% SDS (w/v) 
until the background counts are removed.  
10. Expose the membranes to X-ray film for 36-48 h at -80°C, and determine the level of StAR expression in the different transcripts. 
11. To examine the variation in StAR mRNA expression, re-hybridize the same membranes with a cDNA probe for the human 
GAPDH. Use 42°C for both pre-hybridization and hybridization in the case of the GAPDH probe.  
12. Assess GAPDH expression for verification of RNA loading. 
